Republic Healthcare Limited (8357) AI Stock Analysis

• Market Cap: HK$99.22M
• Dividend Yield: N/A
• Average Volume (3M): 282.67K
• Price to Earnings (P/E): ―
• Beta (1Y): <0.01
• Revenue Growth: -11.68%
• EPS Growth: -71.01%
• Country: HK
• Employees: 34
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: 624,000,000
• 10 Day Avg. Volume: 457,500
• 30 Day Avg. Volume: 282,666
• PEG Ratio: 0.49
• Price to Book (P/B): 0.55
• Price to Sales (P/S): 0.75
• P/FCF Ratio: 134.99
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: HK$0.17 ▲(40.00% Upside)

The score is mainly supported by balance-sheet strength (high equity, low leverage) and some operating improvement (EBIT margin turning positive), but is held back by declining revenue, ongoing net losses, and mixed technical signals (negative MACD and trading below key longer-term moving averages).

Positive Factors

Strong Balance Sheet

An equity ratio above 80% and very low debt-to-equity (0.068) provide durable financial flexibility, lowering refinancing and interest risks. This capital structure supports resilience through downturns and permits funding of operations or strategic initiatives without heavy leverage over the next several months.

Improving Operating Margins

A move to a positive 18.42% EBIT margin signals structural operating improvements or cost discipline. Sustained positive EBIT margin enhances cash generation capacity and indicates the core care-facility operations can reach operational profitability if revenue stabilizes, strengthening long-term viability.

Positive Operating Cash Generation

Operational cash generation despite reported losses shows the business converts core activities into cash. Reliable operating cash reduces near-term reliance on external financing, supports working capital and modest capex, and provides a practical buffer while pursuing longer-term profitability improvements.

Negative Factors

Declining Revenue and Margin Compression

Sustained revenue decline and large gross-margin contraction indicate structural demand, pricing or mix issues. Losing top-line scale undermines ability to absorb fixed costs and jeopardizes margin sustainability, making it harder to translate improved EBIT into stable net profitability over coming quarters.

Ongoing Net Losses & Negative ROE

Continued net losses and negative ROE show the company is not yet generating shareholder returns from its equity base. Persistent losses erode retained capital, limit reinvestment capacity, and could force dilutive financing or cost restructuring if profitable conversion is not achieved within the medium term.

Volatile Free Cash Flow

Fluctuating and declining free cash flow increases execution risk: inconsistent FCF undermines ability to fund capex, expand services, or return capital. Over 2–6 months this variability could constrain strategic investments and make the company more dependent on its limited leverage capacity despite strong equity.

Republic Healthcare Limited Business Overview & Revenue Model

Company Description

Republic Healthcare Limited, a primary healthcare services company, provides consultation, medical investigation, and treatment services in Singapore. The company offers various treatment solutions for common medical conditions and focuses on sexual health and infectious diseases. It also provides treatment solutions for common skin conditions and basic medical aesthetics services. The company operates nine clinics under the Dr. Tan & Partners brand name; and one clinic under the S Aesthetics brand name. Republic Healthcare Limited was founded in 2010 and is headquartered in Singapore.

How the Company Makes Money

Republic Healthcare Limited generates revenue through multiple streams, primarily from its healthcare services offered in hospitals and clinics. The company earns money by charging patients for medical consultations, treatments, and procedures. Additionally, Republic Healthcare collaborates with insurance providers, receiving reimbursements for services rendered to insured patients. Another key revenue stream includes partnerships with pharmaceutical companies for clinical trials and research, where the company may receive funding for conducting studies. Furthermore, the company may generate income from the sale of medical supplies and equipment within its facilities, contributing to its overall revenue.

Republic Healthcare Limited Financial Statement Overview

Summary

Financials are mixed: revenue decline and negative net margins signal ongoing profitability pressure, but the balance sheet is strong (equity ratio >80% and very low debt-to-equity of 0.068). Cash flow is variable, though operating cash flow remains positive relative to net income, and EBIT margin improved to 18.42% in 2024.

Income Statement

Revenue has declined over the past three years, with a negative revenue growth rate and shrinking gross profit margin from 72.1% in 2019 to 24.4% in 2024. The net profit margin is negative, indicating losses. However, the company improved its EBIT margin from negative to 18.42% in 2024, showing some operational efficiency.

Balance Sheet

The company maintains a strong equity position with an equity ratio consistently above 80%. Debt-to-equity ratio is low at 0.068, indicating low financial leverage. However, the return on equity is negative due to net losses, which presents a challenge for profitability.

Cash Flow

The free cash flow has fluctuated, with a decline in free cash flow growth rate in recent periods. The operating cash flow to net income ratio is positive, indicating operational cash generation despite accounting losses. However, the free cash flow to net income ratio is inconsistent, reflecting variability in capital management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.51M	9.23M	10.28M	9.44M	13.97M	13.89M
Gross Profit	1.67M	6.48M	2.70M	5.97M	9.13M	9.83M
EBITDA	-1.30M	-188.79K	29.34K	-387.88K	962.89K	1.43M
Net Income	-1.25M	-178.16K	-855.12K	-1.48M	-997.93K	-143.61K
Balance Sheet
Total Assets	13.65M	14.48M	15.64M	16.42M	19.27M	19.34M
Cash, Cash Equivalents and Short-Term Investments	9.75M	11.52M	11.93M	11.83M	14.27M	13.07M
Total Debt	1.25M	858.22K	961.16K	810.47K	1.55M	2.76M
Total Liabilities	2.34M	1.93M	2.89M	2.30M	3.67M	6.09M
Stockholders Equity	11.31M	12.55M	12.75M	14.12M	15.59M	13.05M
Cash Flow
Free Cash Flow	-1.22M	51.27K	806.24K	-1.16M	-1.13M	232.36K
Operating Cash Flow	-1.15M	125.07K	899.91K	-734.46K	-510.07K	771.30K
Investing Cash Flow	1.24M	-93.94K	831.49K	-987.23K	-1.56M	7.62M
Financing Cash Flow	-560.42K	-531.65K	-587.62K	-689.73K	2.28M	-1.36M

Republic Healthcare Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8357, the sentiment is Positive. The current price of 0.12 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.12, and below the 200-day MA of 0.14, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 70.37 is Negative, neither overbought nor oversold. The STOCH value of 88.10 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8357.

Republic Healthcare Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2293	75 Outperform	HK$197.21M	11.19	7.84%	8.00%	-21.50%	-43.25%
8357	61 Neutral	HK$99.22M	-13.47	-10.31%	―	-11.68%	-71.01%
8307	58 Neutral	HK$79.35M	-60.61	-19.93%	―	-2.91%	55.41%
8161	53 Neutral	HK$22.05M	2.46	125.77%	―	-20.81%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
8143	42 Neutral	HK$193.90M	-6.44	-132.60%	―	-30.45%	-734.38%
8437	41 Neutral	HK$17.32M	-0.58	―	―	14.64%	-81.95%